bioMerieux recalls VIDAS chlamydia assay batches
This article was originally published in Clinica
bioMerieux has recalled in the UK two batches of its VIDAS chlamydia CHL assay, following the discovery of stability problems with a raw material, which is "causing an accelerated degradation of performance". As a result of investigations carried out thus far, the company is urging users to re-test only those patients who were tested since July 24 2003 and for whom the result was negative with a value of 20 or greater.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.